Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Instagram Outage Disrupts Thousands of U.S. Users 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
EDISON, N.J., June 08, 2017 -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at The 2017 Marcum MicroCap Conference being held June 15-16, 2017, at the Grand Hyatt New York in New York City.
James Sapirstein, Chief Executive Officer of ContraVir, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. Mr. Sapirstein was also invited to participate on a panel discussing the topic, "Identifying Breakthrough Opportunities in Life Sciences."
| Event: | ContraVir Company Presentation |
| Date: | Thursday, June 15, 2017 |
| Time: | 10:30 AM – 10:55 AM (Eastern Time) |
| Location: | Broadway - Conference Level |
| Webcast Details: | The presentation will be webcast live and remain available for 90 days following the presentation. To access the webcast, please visit the investor relations section of the ContraVir website at http://ir.contravir.com/events-webcasts |
| Event: | Panel: Identifying Breakthrough Opportunities in Life Sciences |
| Date: | Thursday, June 15, 2017 |
| Time: | 04:00 PM – 05:00 PM (Eastern Time) |
About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The Company is developing two novel anti-HBV compounds with complementary mechanisms of action. TXL™ currently in Phase 2a, is designed to deliver high intrahepatic concentrations of TFV, while minimizing off-target effects caused by high levels of circulating TFV. CRV431, the other anti-HBV compound, is a next-generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. ContraVir is also developing Valnivudine™, an orally available nucleoside analogue prodrug; Valnivudine™ is currently in Phase 3 for the treatment of herpes zoster. In addition to direct antiviral activity, Phase 2 data suggest that Valnivudine™ has the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN). For more information visit www.contravir.com.
For further information, please contact: Sharen Pyatetskaya Director of Investor Relations [email protected]; (732) 902-4028
